1421P - Recommended cancer screening and vulnerable populations: results from the EDIFICE 5 survey

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancers in Adolescents and Young Adults (AYA)
Aetiology, epidemiology, screening and prevention
Basic Scientific Principles
Presenter Jean-François Morere
Citation Annals of Oncology (2017) 28 (suppl_5): v502-v506. 10.1093/annonc/mdx383
Authors J. Morere1, F. Eisinger2, J. Blay3, S. Couraud4, L. Brignoli-Guibaudet5, C. Lhomel6, A. Cortot7, L. Greillier8, J. Viguier9
  • 1Medical Oncology, Hopital Paul Brousse, 94804 - Villejuif/FR
  • 2Aix Marseille Univ, Inserm, Sesstim, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 3Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 4Respiratory Diseases And Thoracic Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 5Statistics, Kantarhealth, Paris/FR
  • 6Medical, Roche - France, 9265000 - Boulogne-Billancourt/FR
  • 7Pneumology-oncology, Hospital Albert Calmette, 59000 - Lille/FR
  • 8Multidisciplinary Oncology And Therapeutic Innovations, Assistance Publique - Hopitaux de Marseille, 13915 - Marseille/FR
  • 9Medical Oncology, CHRU Bretonneau, 37044 - Tours/FR



Based on data from the 2011, 2014 and 2016 EDIFICE surveys, we sought to identify potential links between impoverished living conditions and participation in screening in the context of organized programs (colorectal [CRC], breast [BC] and cervical cancers [CC]).


The EDIFICE observational phone surveys were conducted among representative population samples (age 40-75 yrs in 2011 [N = 1603] and 2014 [N = 1602]; age 50-75 years in 2016 [N = 1501]) using the quota method. Attitudes regarding screening were assessed in subgroups of individuals within the target age-groups for each screening program. Participation in screening and follow-up rates were assessed by asking if respondents had undergone at least one screening examination in their lifetime and within the recommended time frame (2 yrs for CRC and BC, 3 yrs for CC). Data were analyzed according to the validated EPICES vulnerability score.


For CRC, over the period 2011/2014/2016, participation increased in non-vulnerable subgroups (60% vs. 63%, NS and 63% vs. 68%, P = 0.05) as did follow-up rates (34% vs 33%, NS and 33% vs 40%, P = 0.01). Participation (60%/54%/53%) and follow-up (31%/30%/31%) were stable among vulnerable individuals. Participation was lower in vulnerable vs. non-vulnerable individuals in 2014 (P = 0.02) and 2016 (P 


The 2016 EDIFICE survey confirms the increasing impact of social vulnerability on recommended screening programs, particularly for CRC.

Clinical trial identification

Legal entity responsible for the study

Kantar Health




J-F. Morere, F. Eisinger, J-Y. Blay, S. Couraud, A. Cortot, L. Greillier: Honorarium fees from Roche Edifice surveys were funded by Roche S.A. C. Lhomel: Employee of Roche Edifice surveys were funded by Roche S.A. All other authors have declared no conflicts of interest.